Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Butlin RJ"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pappalardi MB; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Keenan K; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Cockerill M; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK.; These authors contributed equally: Mark Cockerill, Wendy A. Kellner., Kellner WA; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA.; These authors contributed equally: Mark Cockerill, Wendy A. Kellner., Stowell A; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Sherk C; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Wong K; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Pathuri S; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Briand J; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Steidel M; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Chapman P; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Groy A; Future Pipeline Discovery, GlaxoSmithKline, Collegeville, PA, USA., Wiseman AK; Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA., McHugh CF; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Campobasso N; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Graves AP; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Fairweather E; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Werner T; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Raoof A; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Butlin RJ; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Rueda L; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Horton JR; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fosbenner DT; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Zhang C; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Handler JL; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Muliaditan M; Drug Metabolism and Pharmacokinetics Modelling, GlaxoSmithKline, Stevenage, UK., Mebrahtu M; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Jaworski JP; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., McNulty DE; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Burt C; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Eberl HC; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Taylor AN; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Ho T; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Merrihew S; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Foley SW; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Rutkowska A; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Li M; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Romeril SP; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Goldberg K; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Zhang X; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kershaw CS; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Bantscheff M; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Jurewicz AJ; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Minthorn E; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Grandi P; Cellzome GmbH, Functional Genomics, GlaxoSmithKline, Heidelberg, Germany., Patel M; Medicinal Science & Technology, GlaxoSmithKline, Collegeville, PA, USA., Benowitz AB; Future Pipeline Discovery, GlaxoSmithKline, Collegeville, PA, USA., Mohammad HP; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Gilmartin AG; Future Pipeline Discovery, GlaxoSmithKline, Collegeville, PA, USA., Prinjha RK; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Ogilvie D; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Carpenter C; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Heerding D; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Baylin SB; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Jones PA; Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA., Cheng X; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., King BW; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Luengo JI; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., Jordan AM; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Waddell I; Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Macclesfield, UK., Kruger RG; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA., McCabe MT; Cancer Epigenetics Research Unit, Oncology, GlaxoSmithKline, Collegeville, PA, USA.
Publikováno v:
Nature cancer [Nat Cancer] 2021 Oct; Vol. 2 (10), pp. 1002-1017. Date of Electronic Publication: 2021 Sep 27.
Autor:
McCoull W; IMED Oncology and Discovery Sciences, AstraZeneca , 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, U.K., Bailey A; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Barton P; IMED Oncology and Discovery Sciences, AstraZeneca , 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, U.K., Birch AM; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Brown AJ; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Butler HS; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Boyd S; IMED Oncology and Discovery Sciences, AstraZeneca , 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, U.K., Butlin RJ; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Chappell B; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Clarkson P; IMED Oncology and Discovery Sciences, AstraZeneca , 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, U.K., Collins S; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Davies RM; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Ertan A; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Hammond CD; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Holmes JL; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Lenaghan C; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Midha A; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Morentin-Gutierrez P; IMED Oncology and Discovery Sciences, AstraZeneca , 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, U.K., Moore JE; IMED CVMD, AstraZeneca , Mereside, Alderley Park, Macclesfield, SK10 4TG, U.K., Raubo P; IMED Oncology and Discovery Sciences, AstraZeneca , 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, U.K., Robb G; IMED Oncology and Discovery Sciences, AstraZeneca , 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2017 Apr 13; Vol. 60 (7), pp. 3187-3197. Date of Electronic Publication: 2017 Apr 04.
Autor:
Barlind JG; Cardiovascular and Gastrointestinal Innovative Medicines Unit Mölndal, AstraZeneca R&D, S-431 83 Mölndal, Sweden., Bauer UA, Birch AM, Birtles S, Buckett LK, Butlin RJ, Davies RD, Eriksson JW, Hammond CD, Hovland R, Johannesson P, Johansson MJ, Kemmitt PD, Lindmark BT, Morentin Gutierrez P, Noeske TA, Nordin A, O'Donnell CJ, Petersson AU, Redzic A, Turnbull AV, Vinblad J
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2012 Dec 13; Vol. 55 (23), pp. 10610-29. Date of Electronic Publication: 2012 Nov 21.
Autor:
Kirkham JD; Department of Chemistry, University of Sheffield, Sheffield, S3 7HF, UK., Butlin RJ, Harrity JP
Publikováno v:
Angewandte Chemie (International ed. in English) [Angew Chem Int Ed Engl] 2012 Jun 25; Vol. 51 (26), pp. 6402-5. Date of Electronic Publication: 2012 May 16.
Autor:
McCoull W; Cardiovascular & Gastrointestinal Innovative Medicines Unit, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. william.mccoull@astrazeneca.com, Addie MS, Birch AM, Birtles S, Buckett LK, Butlin RJ, Bowker SS, Boyd S, Chapman S, Davies RD, Donald CS, Green CP, Jenner C, Kemmitt PD, Leach AG, Moody GC, Gutierrez PM, Newcombe NJ, Nowak T, Packer MJ, Plowright AT, Revill J, Schofield P, Sheldon C, Stokes S, Turnbull AV, Wang SJ, Whalley DP, Wood JM
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Jun 15; Vol. 22 (12), pp. 3873-8. Date of Electronic Publication: 2012 May 02.